New developments in chemotherapy for metastased bladder cancer;Nieuwe ontwikkelingen in chemotherapie bij gemetastaseerde blaaskanker

Nederlands Tijdschrift voor Geneeskunde

Volumn 145, Issue 50, 2001, Pages 2412-2417

  De Wit, R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; DEATH; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; KIDNEY FUNCTION; METASTASIS; MUCOSA INFLAMMATION; SEPSIS;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DOXORUBICIN; HUMANS; MALE; METHOTREXATE; PACLITAXEL; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 0035892891     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Chemotherapy of urothelial tract tumors
2. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium
3. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
4. M-VAC (methotrexate, vinblasline, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience
5. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer
6. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience
7. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
8. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors
9. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
10. Longterm follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: Cause for concern
11. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium
12. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma
13. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: An Eastern Cooperative Oncology Group trial
14. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer
15. Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC
16. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol nr 30924
17. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy
18. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
19. Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer
20. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer
21. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma
22. Oral piritrexim, an effective treatment for metastatic urothelial cancer
23. Significant activity of paclitaxel in advanced transitionalcell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group
24. Docetaxel (Taxotere): An active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients
25. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder
26. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter
27. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer
28. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma
29. Docetaxel and cisplatin in metastatic urothelial cancer: A phase II study
30. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group
31. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial
32. Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract
33. E2895 cisplatin and paclitaxel in advanced carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group (ECOG)
34. Phase II trial of combination paclitaxel and cisplatin in advanced urothelial carcinoma
35. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: The importance of survival as a clinical trial end point
36. Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study
37. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
38. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer
39. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum
40. Single agent 2′,2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: A phase II study
41. Interaction between cisplatin and gemcitabine in vitro and in vivo
42. Mechanisms of synergism between gemcitabine and cisplatin
43. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial
44. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group
45. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
46. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
47. Health care resource use for patients with advanced bladder cancer treated with gemcitabine plus cisplatin (GC) versus MVAC in a phase III trial
48. A dose finding study of carboplatin with fixed dose gemcitabine in unfit patients with advanced bladder cancer
49. Phase I-II Study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium